Europe — EMA
Mivacurium Kalceks
GNH USA supplies Mivacurium Kalceks (Mivacurium), a non‑depolarizing neuromuscular blocker for short‑acting muscle relaxation and intubation.
Request sourcing
What is Mivacurium?
Mivacurium, the active ingredient in Mivacurium Kalceks, is a non-depolarizing neuromuscular blocking agent presented as an injection solution for intravenous use. It facilitates endotracheal intubation and provides short‑acting skeletal muscle relaxation during brief surgical procedures.
GNH USA supplies Mivacurium Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.
What is Mivacurium used for?
Mivacurium is a short‑acting non‑depolarizing neuromuscular blocker used in procedures that require rapid, temporary muscle relaxation.
- Facilitation of endotracheal intubation: provides brief, reliable paralysis to allow safe airway placement. - Short surgical procedures: enables skeletal muscle relaxation for operations typically lasting less than 30 minutes. - Diagnostic procedures requiring muscle relaxation: assists in bronchoscopy, endoscopy or other examinations where brief paralysis improves conditions for the clinician.
What are the side effects of Mivacurium?
Mivacurium may cause a range of adverse reactions that vary in frequency and severity.
Common Side Effects: - Transient hypotension: mild drop in blood pressure shortly after injection. - Flushing or erythema: skin reddening at the injection site or generalized. - Bronchospasm: narrowing of airways, especially in susceptible individuals. - Tachycardia: temporary increase in heart rate. - Nausea or vomiting: gastrointestinal upset following administration. - Headache: mild to moderate headache during recovery.
Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Prolonged apnea: unexpected extension of muscle paralysis beyond the intended period. - Malignant hyperthermia susceptibility: rare hypermetabolic crisis in predisposed patients. - Cardiac arrest: life‑threatening loss of cardiac function. - Severe hypotension: marked blood pressure decline needing vasopressor support. - Respiratory depression: inadequate ventilation after drug effect wears off.
What precautions apply to Mivacurium?
When using Mivacurium, clinicians should observe several safety measures to minimize risk.
- Assess neuromuscular function: monitor depth of blockade with a peripheral nerve stimulator. - Avoid in patients with known hypersensitivity to mivacurium or related compounds. - Use with caution in hepatic or renal impairment: altered metabolism may prolong effect. - Consider dose reduction in elderly or debilitated patients. - Monitor cardiovascular status: watch for hypotension or arrhythmias during infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Mivacurium interact with?
Mivacurium can interact with other agents that influence neuromuscular transmission or cardiovascular stability.
Major Interactions (Avoid): - Other neuromuscular blocking agents: additive paralysis may be profound. - Cholinesterase inhibitors (e.g., neostigmine, pyridostigmine): can potentiate or prolong block. - Aminoglycoside antibiotics (e.g., gentamicin, streptomycin): enhance neuromuscular blockade. - Magnesium salts: increase sensitivity to mivacurium. - Inhalational anesthetics (e.g., sevoflurane, desflurane): synergistic effect on muscle relaxation.
Moderate Interactions (Monitor Closely): - CNS depressants (e.g., propofol, benzodiazepines): may deepen sedation when combined. - Beta‑blockers: can accentuate bradycardia if hypotension occurs. - Calcium channel blockers: may affect hemodynamic response. - Diuretics that alter electrolyte balance: monitor for enhanced blockade. - Antihistamines: possible additive effect on hypotension.
